Elicera Therapeutics AB (ELIC) Stock Statistics & Valuation Metrics

Elicera Therapeutics AB has a market cap or net worth of kr195.54M. The enterprise value is kr123.71M.

Elicera Therapeutics AB has 66,736,374 shares outstanding. The number of shares has decreased by -2.65% in one year.

Elicera Therapeutics AB’s return on equity (ROE) is -0.75 and return on invested capital (ROIC) is -76.81%.

The current PE Ratio of Elicera Therapeutics AB is ―. Elicera Therapeutics AB’s PEG ratio is 0.54.

In the last 12 months, Elicera Therapeutics AB had revenue of 0.00 and earned -17.41M in profits. Earnings per share was -0.38.

In the last 12 months, operating cash flow was -21.55M and capital expenditures 0.00, giving a free cash flow of -21.55M billion.

Elicera Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―

Elicera Therapeutics AB upcoming earnings date is Aug 21, 2026, Before Open (Confirmed).

Elicera Therapeutics AB as a current ratio of 6.75, with Debt / Equity ratio of 0.00%

In the past 12 months, Elicera Therapeutics AB has paid 0.00 in taxes.

Elicera Therapeutics AB EV to EBITDA ratio is -12.25, with an EV/FCF ratio of -9.89.

Elicera Therapeutics AB has kr24.85M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr24.85M billion.

Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Elicera Therapeutics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―